Guardian Pharmacy Services, Inc
28.55-1.01 (-3.42%)
Oct 29, 4:00:02 PM EDT · NYSE · GRDN · USD
Key Stats
Market Cap
1.81BP/E (TTM)
-Basic EPS (TTM)
-1.48Dividend Yield
0%Recent Filings
8-K
Insiders extend stock lock-up
Guardian Pharmacy Services locked up shares held by insiders covering 93% of outstanding Class A and B common stock through June 30, 2026, starting October 19, 2025, after prior agreements expire. This restricts 17.2 million Class A shares now and 12.8 million more upon Class B conversion in March 2026, signaling strong insider confidence amid post-IPO stability. Commitments bind tightly. Yet extensions remain possible by mutual consent.
8-K
Guardian's Q2 growth presentation
Guardian Pharmacy Services released an investor presentation on September 18, 2025, highlighting its leadership in the $7 billion ALF pharmacy market with 13% national share across 11 states. The company reported Q2 2025 revenue of $344.3 million, up from $300 million in Q2 2024, alongside adjusted EBITDA of $25 million, reflecting 15.8% revenue CAGR since 2012. Organic growth via new facilities and acquisitions drives scale, yet integration risks could temper accretion timelines.
10-Q
Q2 FY2025 results
Guardian Pharmacy Services posted solid Q2 FY2025 results, with revenue climbing 14.8% year-over-year to $344.3M, fueled by organic growth in residents served and prescriptions dispensed alongside acquisitions adding $9.9M; gross profit rose to $68.1M, but operating income dipped to $12.6M from $17.0M last year as SG&A swelled 25.5% to $55.6M, driven by higher headcount and $4.4M in share-based compensation. Net income attributable to the company hit $9.0M, or $0.14 diluted EPS on 63.2M shares, while YTD figures show revenue up 17.1% to $673.6M and EPS at $0.29, reconciling cleanly with weighted shares. Cash swelled to $18.8M, with operating cash flow steady at $37.5M and free cash flow of $27.4M after $10.1M capex; the $40M credit line sits fully available, no debt outstanding. Acquisitions in Q2 closed for $11.1M total consideration (cash/deferred/contingent), recognizing $6.9M goodwill and $4.4M intangibles amortized over 10 years for customer lists. Revenue growth persists. Yet regulatory pressures on pharmacy reimbursements loom large.
8-K
Guardian raises FY guidance
Guardian Pharmacy Services reported Q2 2025 revenue of $344.3 million, up 15% year-over-year, fueled by organic growth and acquisitions, while resident count hit over 195,000, a 12% rise. Adjusted EBITDA climbed to $25.0 million from $21.7 million last year, despite public company costs; net income dipped to $8.8 million from $15.8 million due to taxes and share-based compensation. The company raised full-year guidance to $1.39-$1.41 billion in revenue and $100-$102 million in Adjusted EBITDA. Acquisitions expanded its footprint, but legal proceedings pose risks.
8-K
Guardian's Investor Day highlights
Guardian Pharmacy Services hosted its Investor Day on June 18, 2025, unveiling a presentation that spotlights its ALF market leadership with 53 pharmacies across 11 states, serving 189,000 residents and dispensing 27 million Rx's annually. The company detailed a disciplined growth strategy blending organic expansion and acquisitions, projecting continued market share gains through smarter tech and lasting partnerships. Adjusted EBITDA hit $90.8 million in 2024, underscoring robust financials amid forward-looking risks like regulatory shifts. Acquisitions unlock value fast.
IPO
Website
Employees
Sector
Industry
BTSG
BrightSpring Health Services, I
34.05+0.05
HCSG
Healthcare Services Group, Inc.
18.81-0.42
LFST
LifeStance Health Group, Inc.
4.98-0.12
LWSCF
Sienna Sr Living Inc.
13.58-0.48
NHC
National HealthCare Corporation
120.85-1.15
NUTX
Nutex Health Inc.
127.83-0.85
PACS
PACS Group, Inc.
12.44+0.02
PNTG
The Pennant Group, Inc.
25.03-0.86
SNDA
Sonida Senior Living, Inc.
25.73-0.44
SRXH
SRX Health Solutions, Inc.
0.34-0.03